Last reviewed · How we verify
polysaccharide
At a glance
| Generic name | polysaccharide |
|---|---|
| Sponsor | Pfizer |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
- Pharmacokinetic and Subjective Effects of Heated Tobacco Products (NA)
- The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics (NA)
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (PHASE2)
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial (PHASE2)
- Effects of Different Caffeine Forms on Aerobic and Anaerobic Exercise Performance (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- polysaccharide CI brief — competitive landscape report
- polysaccharide updates RSS · CI watch RSS
- Pfizer portfolio CI